Research programme: anticancer nanotherapeutics - Immune Pharmaceuticals

Drug Profile

Research programme: anticancer nanotherapeutics - Immune Pharmaceuticals

Alternative Names: Anti-EGFR NanomAbs; Anti-H-ferritin NanomAbs; Anti-HER2 NanomAbs; Antibody nanoparticle conjugates - Immune Pharmaceuticals; Monoclonal antibody-nanomedicine conjugates - Immune Pharmaceuticals; Nano-therapeutics - Immune Pharmaceuticals; NanomAbs®

Latest Information Update: 21 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Pharmaceuticals
  • Developer Immune Pharmaceuticals Ltd
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 May 2015 Preclinical trials in Cancer in Israel (unspecified route) before May 2015 (Immune Pharmaceuticals pipeline)
  • 26 Aug 2013 Immune Pharmaceuticals Ltd has merged with EpiCept Corp to form Immune Pharmaceuticals Inc
  • 23 May 2012 Early research in Cancer in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top